Cys-PKHB1

Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death[1][2].

Product Specifications

CAS Number

[2378833-51-1]

Product Name Alternative

Cys-txCD47

UNSPSC

12352209

Target

CD47; Reactive Oxygen Species (ROS) ; Thrombopoietin Receptor

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Smiles

NCCCC[C@H](C(O)=O)NC([C@H](CCCCN)NC([C@@H](NC([C@H](CCSC)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@@H](CCCCN)NC([C@@H](N)CS)=O)=O)=O)CC1=CC=CC=C1)=O)CC2=CC=C(C=C2)O)=O)=O)=O)=O)CC3=CNC4=CC=CC=C34)=O)=O

Molecular Formula

C71H110N18O13S2

Molecular Weight

1487.88

References & Citations

[1]Mohanty A, et al. Protein-Caged Nanoparticles: A Promising Nanomedicine Against Cancer. Chonnam Med J. 2023 Jan;59 (1) :1-12.|[2]Calvillo-Rodríguez KM, et al. PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells. Oncoimmunology. 2022 Apr 4;11 (1) :2054305.